Cancer of connective tissue can take a variety of forms, each requiring its own specific research for drug development and understanding proliferation pathways. Fibrosarcomas, which are cancers of fibrous connective tissue characterized by immature fibroblasts, affect human infants and middle-aged males. Derived in 1972, the HT-1080 cell line can be used as a testing ground for drug research and a model for fibrosarcoma research involving genetic screening. Transfection of siRNA sequences, essential for RNAi technology, can be accomplished through state-of-the-art lipid transfection reagents, ensuring that the cells give realistic responses that can inform drug development. HT-1080 cells, though susceptible to a variety of viruses, can still be useful tools for preclinical research specific to fibrosarcomas.
The HT-1080 cell line comes from tumorigenic connective tissue originally removed from a 35-year-old male Caucasian patient with fibrosarcoma in 1972. These cells have a susceptibility to an assortment of viruses such as the RD-114 feline virus, polio, vesicular stomatitis virus and feline leukemia virus. These cells are used in research involving connective tissue cancer. Altogen Biosystems facilitates these research studies by manufacturing an HT-1080 transfection reagent for fibrosarcoma cells. The reagent has a high transfection efficacy for siRNA delivery. Transfection Reagent for HT-1080 Cells (Fibrosarcoma Cells, CCL-121)
Comments
Post a Comment